Valuation
- Market cap
- 17,169,000
- Revenue TTM
- $2,290,000
- Net income TTM
- $-18,630,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -813.54%
- Debt to equity
- 0.90
Trading
- Volume
- 252,600
- Avg volume
- 905,228
- Day's range
- $1.96 – $2.19
- Shares out
- 8,375,000
- Stochastic %K
- 12%
- Beta
- -2.16
- Analysts
- Strong Sell
- Price target
- $10.00
Company profile
Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an end...
Show more
Femasys Inc., a biomedical company, develops and commercializes therapeutic and diagnostic products for women's reproductive health needs in the United States and internationally. The company offers FemaSeed, an intratubal insemination device; FemVue, a companion diagnostic for fallopian tube assessment through ultrasound; FemSperm, a sperm handling kit; FemChec, a confirmation test for tubal patency; FemCerv, an endocervical tissue sampler for cervical cancer diagnosis; and FemCath, a cornual balloon catheter for selective tube evaluation. It also provides FemBloc, a non-surgical female permanent birth control solution. The company offers its products to gynecological physicians, related healthcare professionals, and women's healthcare provider organizations. Femasys Inc. was incorporated in 2004 and is headquartered in Suwanee, Georgia.
- Industry
- Medical Instruments & Supplies
- Sector
- Healthcare
- Phone
- 770 500 3910
- Website
- https://femasys.com
- Address
- 3950 Johns Creek Court, Suite 100, Suwanee, United States
Latest news
No headlines yet.
